Skip to content

Study · Animal study (in vivo) · mouse · 2022

8 results

The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.

Yin Y, Pan Y, He J, Zhong H, Wu Y, Ji C, Liu L, Cui X

Pharmacological research17 Nov 2021Cited by 55 (Europe PMC)

PMID34798268 (opens in a new tab)DOI10.1016/j.phrs.2021.105987 (opens in a new tab)PepBankPUB-34798268
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with gestational diabetes, MOTS‑c significantly alleviated hyperglycemia.

    In plain wordsIn mice with gestational diabetes, MOTS‑c lowered high blood sugar.

    Peptide
    MOTS-c
    Outcome
    DecreaseHyperglycemia
    Study

    mousen: not reported in source

    Gestational diabetes (short-term high-fat diet plus low-dose streptozotocin)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · Daily during pregnancyAs given in this study (mouse).

    Source sentences

    Summary
    MOTS-c significantly alleviated hyperglycemia, improved insulin sensitivity and glucose tolerance, and reduced birth weight and the death of offspring induced by GDM.
    1 context sentence
    Summary · context
    A GDM mouse model was established by short term high-fat diet combined with low-dose streptozotocin (STZ) treatment while MOTS-c was administrated daily during pregnancy.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with gestational diabetes, MOTS‑c improved insulin sensitivity.

    In plain wordsIn mice with gestational diabetes, MOTS‑c improved how well the body responds to insulin.

    Peptide
    MOTS-c
    Outcome
    IncreaseInsulin sensitivity
    Study

    mousen: not reported in source

    Gestational diabetes (short-term high-fat diet plus low-dose streptozotocin)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · Daily during pregnancyAs given in this study (mouse).

    Source sentences

    Summary
    improved insulin sensitivity and glucose tolerance, and reduced birth weight and the death of offspring induced by GDM.
    1 context sentence
    Summary · context
    A GDM mouse model was established by short term high-fat diet combined with low-dose streptozotocin (STZ) treatment while MOTS-c was administrated daily during pregnancy.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with gestational diabetes, MOTS‑c improved glucose tolerance.

    In plain wordsIn mice with gestational diabetes, MOTS‑c improved the body's handling of a sugar load.

    Peptide
    MOTS-c
    Outcome
    IncreaseGlucose tolerance
    Study

    mousen: not reported in source

    Gestational diabetes (short-term high-fat diet plus low-dose streptozotocin)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · Daily during pregnancyAs given in this study (mouse).

    Source sentences

    Summary
    improved insulin sensitivity and glucose tolerance, and reduced birth weight and the death of offspring induced by GDM.
    1 context sentence
    Summary · context
    A GDM mouse model was established by short term high-fat diet combined with low-dose streptozotocin (STZ) treatment while MOTS-c was administrated daily during pregnancy.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with gestational diabetes, MOTS‑c reduced the birth weight induced by gestational diabetes.

    In plain wordsIn mice with gestational diabetes, MOTS‑c reduced the pup birth weight induced by the condition.

    Peptide
    MOTS-c
    Outcome
    DecreaseBirth weight of offspring
    Study

    mousen: not reported in source

    Gestational diabetes (short-term high-fat diet plus low-dose streptozotocin)
    Outcome group
    Labour and delivery outcomes · Reproductive and sexual health
    Studied dose
    Dose not stated · Daily during pregnancyAs given in this study (mouse).

    Source sentences

    Summary
    reduced birth weight and the death of offspring induced by GDM.
    1 context sentence
    Summary · context
    A GDM mouse model was established by short term high-fat diet combined with low-dose streptozotocin (STZ) treatment while MOTS-c was administrated daily during pregnancy.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In mice with gestational diabetes, MOTS‑c reduced the death of offspring induced by gestational diabetes.

    In plain wordsIn mice with gestational diabetes, MOTS‑c reduced the deaths of pups caused by the condition.

    Peptide
    MOTS-c
    Outcome
    DecreaseDeath of offspring
    Study

    mousen: not reported in source

    Gestational diabetes (short-term high-fat diet plus low-dose streptozotocin)
    Outcome group
    Labour and delivery outcomes · Reproductive and sexual health
    Studied dose
    Dose not stated · Daily during pregnancyAs given in this study (mouse).

    Source sentences

    Summary
    reduced birth weight and the death of offspring induced by GDM.
    1 context sentence
    Summary · context
    A GDM mouse model was established by short term high-fat diet combined with low-dose streptozotocin (STZ) treatment while MOTS-c was administrated daily during pregnancy.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice with gestational diabetes, MOTS‑c activated insulin sensitivity in skeletal muscle.

    In plain wordsIn mice with gestational diabetes, MOTS‑c improved insulin response in muscle.

    Peptide
    MOTS-c
    Outcome
    IncreaseInsulin sensitivity in skeletal muscle
    Study

    mousen: not reported in source

    Gestational diabetes (short-term high-fat diet plus low-dose streptozotocin)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · Daily during pregnancyAs given in this study (mouse).

    Source sentences

    Summary
    MOTS-c also could activate insulin sensitivity in the skeletal muscle of GDM mice and elevate glucose uptake in vitro.
    1 context sentence
    Summary · context
    A GDM mouse model was established by short term high-fat diet combined with low-dose streptozotocin (STZ) treatment while MOTS-c was administrated daily during pregnancy.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    MOTS‑c protected pancreatic beta cells from streptozotocin-mediated injury; the abstract does not state whether this was shown in mice or in cells.

    In plain wordsMOTS‑c protected insulin-making cells from streptozotocin damage; the abstract does not say whether this was in mice or in cells.

    Peptide
    MOTS-c
    Outcome
    DecreasePancreatic beta-cell protection from streptozotocin injury
    Study

    mousen: not reported in source

    Gestational diabetes (short-term high-fat diet plus low-dose streptozotocin)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · Daily during pregnancyAs given in this study (mouse).

    Source sentences

    Summary
    In addition, we found that MOTS-c protects pancreatic β-cell from STZ-mediated injury.
    1 context sentence
    Summary · context
    A GDM mouse model was established by short term high-fat diet combined with low-dose streptozotocin (STZ) treatment while MOTS-c was administrated daily during pregnancy.
  8. 08LabIn vitro (cells)Mechanism

    In vitro, MOTS‑c elevated glucose uptake.

    In plain wordsIn cells, MOTS‑c increased sugar uptake.

    Peptide
    MOTS-c
    Outcome
    IncreaseGlucose uptake in vitro
    Study

    n: not reported in source

    In vitro (cell type not stated)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    elevate glucose uptake in vitro.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.